AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03040193
Drug: Lignocaine Nebulization
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% Lignocaine delivered via Nebulization
Trial: NCT01005433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
Trial: NCT03040193
Drug: Saline Nebulization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Delivered via Nebulization
Trial: NCT03601988
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy group receive 8 cycles of XELOX.
Trial: NCT02590809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given for 30 days
Trial: NCT02688361
Drug: Fluimucil® 2% solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
Trial: NCT02066545
Drug: CLS001 Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02066545
Drug: CLS001 Topical Gel Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03453931
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high dose corticosteroids
Trial: NCT01677039
Drug: Test formulation administered with 20% ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
Trial: NCT00688961
Drug: omega-3 acid ethyl esters
RxNorm normalized name: omega-3 acid ethyl esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4, 1 g capsules q.d.
Trial: NCT02554396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline ophthalmic solution
Trial: NCT00647348
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80mg simvastatin oral once daily for 24 months
Trial: NCT00647348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo tablet once daily for 24 months
Trial: NCT00251758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
Trial: NCT00908934
Drug: AZD9056 formulation Phase III 50 mg (T)
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 50 mg tablet (T)
Trial: NCT00908934
Drug: AZD9056 formulation Phase IIb 50 mg (R)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 50 mg tablet (R)
Trial: NCT00908934
Drug: AZD9056 formulation Phase III 200 mg (T)
RxNorm normalized name: CARDIOTOXIN III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 400 mg (2 x 200 mg tablet (T))
Trial: NCT02015533
Drug: CR8020
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
Trial: NCT00908934
Drug: AZD9056 formulation Phase IIb 200mg (R)
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as 400 mg (2 x 200 mg tablet (R))
Trial: NCT02015533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a single 2-hour intravenous infusion.
Trial: NCT00811187
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5cc Normal Saline injection in each paracervical region
Trial: NCT02817503
Drug: Standard BP control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
Trial: NCT02817503
Drug: Moderate BP control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
Trial: NCT02426099
Drug: Low dose spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week add-on low dose spironolactone in resistant hypertension
Trial: NCT02033512
Drug: Transdermal Nanoformulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
Trial: NCT02033512
Drug: Transdermal formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
Trial: NCT01621009
Drug: Placebo medication + counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.~Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day.
Trial: NCT01621009
Drug: Placebo medication, No counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.~Counseling: No counseling, just medication checks
Trial: NCT01715051
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
Trial: NCT01715051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
Trial: NCT00718705
Drug: Josamycin
RxNorm normalized name: josamycin
DrugBank: Josamycin (DB01321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: josamycin with posology of 2 grams per day by oral way during 10 days
Trial: NCT04040686
Drug: Injection of 99mTc-NM-02
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be injected with microdose (\<100ug) of 99mTc-NM-02 radiotracer
Trial: NCT00102323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
Trial: NCT00718705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with posology of 2 grams per day by oral way during 10 days
Trial: NCT02992665
Drug: Ca Ionophore A23187
RxNorm normalized name: iodophors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
Trial: NCT04992442
Drug: [14C]TAK-935 IV Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-935 IV infusion
Trial: NCT04992442
Drug: [14C]TAK-935 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]TAK-935 oral solution
Trial: NCT03260283
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
Trial: NCT02760862
Drug: hydrocortisone 100mg.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
Trial: NCT00648700
Drug: Levothyroxine Sodium Tablets 300 μg
RxNorm normalized name: levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2x300mcg, single dose fasting
Trial: NCT00648700
Drug: Levothroid® Tablets 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2x300mcg, single dose fasting
Trial: NCT00549614
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, 250 mg, 4 times daily for 28 days
Trial: NCT03463083
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All cases of spine surgery will be done under G.A with the patient in prone position. After surgury an epidural catheter will be placed through a separate skin puncture above the incision The catheter will be positioned up to 7 cm from skin entry directing downwards in the epidural space . Once the patient in the post-operative room will be noted to have pain (VAS) of\>4, the study will start. A test dose of 3 ml lignocaine with adrenaline will be injected the following parameters will be noted .~1. The pain score, by using VAS~2. Onset of analgesia (fall of VAS\<4 ).~3. Peak level of analgesia ( VAS score 0).~4. Duration of analgesia (once the patient asks fwith VAS\>4).~5. Monitoring of NIBP, pulse rate, respiratory rate every 30 min.~6. Side-effects such as nausea, vomiting, respiratory depression, Motor blockade Bromage scale\>1 Also deep sedation Ramsay sedation scale\>3 , And shivering and hypotension.
Trial: NCT02072447
Drug: YH4808 PO and [14C]-YH4808 IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01757808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo at a dose of 500mg for one month followed by a dose of 1000mg.
Trial: NCT00498537
Drug: spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01066572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo; identical tablets to Lisinopril.
Trial: NCT00577629
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
Trial: NCT00577629
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
Trial: NCT01981616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion
Trial: NCT00546130
Drug: Krestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
Trial: NCT02759198
Drug: YH23537
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
Trial: NCT02759198
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Celecoxib 200mg
Trial: NCT02759198
Drug: YH23537 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
Trial: NCT02373254
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 400 mg and 800 mg
Trial: NCT02373254
Drug: Acetaminophen/hydrocodone
RxNorm normalized name: ACETAMINOPHEN/HYDROCODONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norco 5/325 mg and 10/325 mg
Trial: NCT00437736
Drug: APO010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
Trial: NCT02867878
Drug: Adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01213238
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
Trial: NCT02624310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01439152
Drug: BAY94-9343
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY94-9343 was administered intravenously in this study. The starting dose for this first-in-man study was 0.15 mg/kg administered as a 1 hour infusion every 21 days.
Trial: NCT01439152
Drug: BAY94-9343 (1.8 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Trial: NCT01439152
Drug: BAY94-9343 (2.2 mg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY94-9343 was administered intravenously in this study. The dose for this cohort was 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
Trial: NCT01020123
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different doses of AZD1656 administered to 5 groups of patients
Trial: NCT01020123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1656 placebo and glipizide placebo administered to 1 group of patients
Trial: NCT01911741
Drug: MDV3100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00004145
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03541603
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile 2.5mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Trial: NCT03343301
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified FOLFOX6 regimen consists of the following:~* Oxaliplatin 85 mg/m² IV infusion over 120 minutes~* Leucovorin 400 mg/m² IV infusion over 120 minutes, or 200 mg/m² levo-leucovorin if leucovorin is unavailable~* 5-fluorouracil (5-FU) 400 mg/m² bolus over approximately 5 minutes then 5-FU 2400 mg/m² as a continuous IV infusion over approximately 48 hours.
Trial: NCT02027220
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
Trial: NCT03437668
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT04087096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered at postoperative months 1, 7, and 13
Trial: NCT04087096
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid 5mg will be administered intravenously at postoperative month 19
Trial: NCT01058408
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally once a day
Trial: NCT04206579
Drug: 10% Dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A mixture of 150 cc dextrose 10% in oral formulation
Trial: NCT01800825
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
Trial: NCT01800825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This will be an identical placebo comparator made of starch.
Trial: NCT00049244
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00721799
Drug: 18F-Fluorothymidine PET scan
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
Trial: NCT02673840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
Trial: NCT02177500
Drug: Telmisartan + hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02177500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02629783
Drug: corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
Trial: NCT02800811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
Trial: NCT00770211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
Trial: NCT04155645
Drug: AZD8233 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive SC dose of AZD8233 (dose 1, dose 2, and dose 3) injection.
Trial: NCT04155645
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive SC dose of placebo injection.
Trial: NCT00003957
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02301234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Trial: NCT02301234
Drug: Celecoxib 100 mg
RxNorm normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Trial: NCT02301234
Drug: Celecoxib 100 mg Matching Placebo
RxNorm normalized name: celecoxib 100 MG
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Trial: NCT01966471
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Trial: NCT01966471
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
Trial: NCT02900027
Drug: APOC-III-L-Rx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
Trial: NCT02002663
Drug: Methylprednisolone 1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02002663
Drug: saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00471263
Drug: Casimax
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01384877
Drug: Placebo (D5W)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
Trial: NCT01677286
Drug: Doxycycline 100 mg po bid x 12 months
RxNorm normalized name: doxycycline monohydrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg by mouth twice daily for 1 year.
Trial: NCT00471263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02265367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00668616
Drug: Cyclophosphamide, Epirubicin, Paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
Trial: NCT05319275
Drug: Acetyllevocarnitine Hydrochloride Tablets
RxNorm normalized name: acetylcarnitine hydrochloride
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg (2×250 mg/tablet) after meal, 3 times per day